Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Screening for gestational diabetes has long been a controversial topic. A previous Health Technology Assessment (HTA) report reviewed literature on screening for gestational diabetes mellitus (GDM) and assessed the case for screening against the criteria set by the National Screening Committee. OBJECTIVE: To update a previous HTA report which reviewed the literature on screening for GDM by examining evidence that has emerged since that last report, including the Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS), the Maternal and Fetal Medicine Units Network (MFMUN) trial and the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study. To review data on recent trends in maternal age at birth and on the prevalence of overweight and obesity and the effect on prevalence of GDM. DATA SOURCES: A systematic review and meta-analysis of the literature was carried out. The bibliographic databases used were MEDLINE (1996 to January 2009), EMBASE (1996 to December 2009), the Cochrane Library 2008 issue 4, the Centre for Reviews and Dissemination database and the Web of Science. REVIEW METHODS: For the review of treatment with oral drugs versus insulin, a full systematic review and meta-analysis was carried out. The results of the ACHOIS, MFMUN and HAPO studies were summarised and their implications discussed. Findings of a selection of other recent studies, relevant to the continuum issue, were summarised. Some recent screening studies were reviewed, including a particular focus on studies of screening earlier in pregnancy. RESULTS: The HAPO results showed a linear relationship between plasma glucose and adverse outcomes - there is a continuum of risk with no clear threshold which could divide women into those with gestational diabetes and those without. There was good evidence from trials and the meta-analysis that women who fail to control hyperglycaemic in pregnancy on lifestyle measures alone can be safely and effectively be treated with oral agents, metformin or glibenclamide, rather than going directly to insulin. Evidence showed few differences in results between glibenclamide and insulin and metformin and insulin. The exceptions were that there was less maternal hypoglycaemia with glibenclamide, but less neonatal hypoglycaemia and lower birthweight with insulin, and there was less maternal weight gain with metformin. The ACHOIS and MFMUN trials showed reductions in perinatal complications among infants born to mothers who were provided with more intensive dietary advice, blood glucose monitoring and insulin when required. The HAPO study demonstrated adverse outcomes over a much wider range of blood glucose (BG) than the traditional definition of GDM. In the HAPO study, no one measure of BG came out as being clearly the best, although fasting plasma glucose (FPG) was as good as any, and had advantages of being more convenient than an oral glucose tolerance test (OGTT), but correlations between fasting and post-load levels were quite poor. Two screening strategies dominated; (1) selection by the American Diabetes Association criteria followed by the 75-g OGTT [incremental cost-effectiveness ratio (ICER) 3678 pounds], and (2) selection by high-risk ethnicity followed by the 75-g OGTT (ICER 21,739 pounds). Studies indicated that costs are about 1833 pounds higher for pregnancies complicated by gestational diabetes, suggesting that prevention would be worthwhile. LIMITATIONS: Not all of the HAPO results have been published, and none of the reviewed economic studies resolved the most difficult issue - at what level of BG does intervention become cost-effective? CONCLUSIONS: The evidence base has improved since the last HTA review in 2002. There is now good evidence for treatment of oral drugs instead of insulin and it looks increasingly as if FPG could be the test of choice. However some key uncertainties remain to be resolved, which can be done by further analysis of the already collected HAPO data and by using the UK model used in developing the NICE guidelines to assess the cost-effectiveness of intervention in each of the seven HAPO categories.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) · Diabetes Care · doi:10.2337/dc09-1848 · Cited by 5,390
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
Bellamy, L., Casas, J.-P., Hingorani, A. D., & Williams, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60731-5 · Cited by 3,253 · cited 2×
“The risk of T2DM has been thoroughly reviewed by Bellamy et al. (2009),132 with a meta-analysis showing that women who had had GDM (defined in various ways) had a relative risk of 7.4 compared with those who were normoglycaemic during pregnancy.”
InfluentialEffect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122
Metzger, B. E., Buchanan, T. A., Coustan, D. R., de Leiva, A., Dunger, D. B., Hadden, D. R., Hod, M., Kitzmiller, J. L., Kjos, S. L., Oats, J. N., et al. (2007) · Diabetes Care · doi:10.2337/dc07-s225 · Cited by 1,908
Self-citationEvaluating patient-based outcome measures for use in clinical trials.
Fitzpatrick, Davey, Buxton, & Jones (1998) · Health Technology Assessment · doi:10.3310/hta2140 · Cited by 1,715
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Qualitative research methods in health technology assessment: a review of the literature.
Murphy, Dingwall, Greatbatch, Parker, & Watson (1998) · Health Technology Assessment · doi:10.3310/hta2160 · Cited by 1,107
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041
Quality-of-life measures in chronic diseases of childhood
Eiser, C., & Morse, R. (2001) · Health Technology Assessment · doi:10.3310/hta5040 · Cited by 872
Torloni, M. R., Betrán, A. P., Horta, B. L., Nakamura, M. U., Atallah, A. N., Moron, A. F., & Valente, O. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2008.00541.x · Cited by 739
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study
The HAPO Study Cooperative Research Group (2009) · Diabetes · doi:10.2337/db08-1112 · Cited by 702
Moher, D., Pham, B., Lawson, M., & Klassen, T. (2003) · Health Technology Assessment · doi:10.3310/hta7410 · Cited by 500
Rubin, G., Potts, H., & Michie, S. (2010) · Health Technology Assessment · doi:10.3310/hta14340-03 · Cited by 435
The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study
HAPO Study Cooperative Research Group (2002) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(02)00092-9 · Cited by 401
Oliver, S., Clarke-Jones, L., Rees, R., Milne, R., Buchanan, P., Gabbay, J., Gyte, G., Oakley, A., & Stein, K. (2004) · Health Technology Assessment · doi:10.3310/hta8150 · Cited by 400
Churchill, R., Hunot, V., Corney, R., Knapp, M., McGuire, H., Tylee, A., & Wessely, S. (2002) · Health Technology Assessment · doi:10.3310/hta5350 · Cited by 368
Kaltenthaler, E., Brazier, J., De Nigris, E., Tumur, I., Ferriter, M., Beverley, C., Parry, G., Rooney, G., & Sutcliffe, P. (2006) · Health Technology Assessment · doi:10.3310/hta10330 · Cited by 357
Screening for type 2 diabetes: literature review and economic modelling
Waugh, N., Scotland, G., McNamee, P., Gillett, M., Brennan, A., Goyder, E., Williams, R., & John, A. (2007) · Health Technology Assessment · doi:10.3310/hta11170 · Cited by 298
Self-citationElkan, Kendrick, Hewitt, Robinson, Tolley, Blair, Dewey, Williams, & Brummell (2000) · Health Technology Assessment · doi:10.3310/hta4130 · Cited by 297
Self-monitoring of blood glucose in type 2 diabetes: systematic review
Clar, C., Barnard, K., Cummins, E., Royle, P., & Waugh, N. (2010) · Health Technology Assessment · doi:10.3310/hta14120 · Cited by 274
Self-citationRoyle, P., & Waugh, N. (2003) · Health Technology Assessment · doi:10.3310/hta7340 · Cited by 194
Self-citationJacobson, G. F., Ramos, G. A., Ching, J. Y., Kirby, R. S., Ferrara, A., & Field, D. R. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.03.018 · Cited by 177
Psychological treatment for insomnia in the regulation of long-term hypnotic drug use
Morgan, K., Dixon, S., Mathers, N., Thompson, J., & Tomeny, M. (2004) · Health Technology Assessment · doi:10.3310/hta8080 · Cited by 166
Issues in methodological research: perspectives from researchers and commissioners
Lilford, R. J., Richardson, A., Stevens, A., Fitzpatrick, R., Edwards, S., Rock, F., & Hutton, J. L. (2001) · Health Technology Assessment · doi:10.3310/hta5080 · Cited by 132
Chmait, R., Dinise, T., & Moore, T. (2004) · Journal of Perinatology · doi:10.1038/sj.jp.7211147 · Cited by 118
Use of glyburide for the treatment of gestational diabetes: the San Antonio experience
Conway, D. L., Gonzales, O., & Skiver, D. (2004) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050310001650725 · Cited by 112
Moss, J. R., Crowther, C. A., Hiller, J. E., Willson, K. J., Robinson, J. S., & The Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group (2007) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-7-27 · Cited by 97 · cited 1×
“Treatment of gestational diabetes: cost-effectiveness studies Moss et al. (2007)120 undertook a cost consequence analysis of the Australian ACHOIS trial,18 within which women diagnosed with mild gestational diabetes defined by a 75-g fasting OGTT result overnight of less than 7.8 mmol/l and after 2…”
InfluentialPredictors of glyburide failure in the treatment of gestational diabetes
Kahn, B. F., Davies, J. K., Lynch, A. M., Reynolds, R. M., & Barbour, L. A. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000218704.28313.36 · Cited by 85
Rochon, M., Rand, L., Roth, L., & Gaddipati, S. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.07.029 · Cited by 82
Naylor, C. D. (1996) · JAMA · doi:10.1001/jama.275.15.1165 · Cited by 67
Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis
Goetzl, L., & Wilkins, I. (2002) · Journal of Perinatology · doi:10.1038/sj.jp.7210759 · Cited by 54 · cited 1×
“Goetzl and Wilkins (2002)117 undertook a decision tree analysis of the costs of glyburide therapy compared with insulin therapy for patients with gestational diabetes.”
Tan, P. C., Ling, L. P., & Omar, S. Z. (2009) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2008.11.038 · Cited by 51 · cited 1×
“In Malaysia, Tan et al. (2009)43 also looked at outcomes in an abnormal GCT but normal OGTT group, and found that some adverse outcomes were increased, though increases were small.”
Ramos, G. A., Jacobson, G. F., Kirby, R. S., Ching, J. Y., & Field, D. R. (2007) · Journal of Perinatology · doi:10.1038/sj.jp.7211683 · Cited by 44
Cited by
Balsells, M., Garcia-Patterson, A., Sola, I., Roque, M., Gich, I., & Corcoy, R. (2015) · BMJ · doi:10.1136/bmj.h102 · Cited by 498
Buckley, B. S., Harreiter, J., Damm, P., Corcoy, R., Chico, A., Simmons, D., Vellinga, A., Dunne, F., & on behalf of the DALI Core Investigator Group (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03541.x · Cited by 360
Camelo Castillo, W., Boggess, K., Stürmer, T., Brookhart, M. A., Benjamin, D. K., & Jonsson Funk, M. (2014) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000285 · Cited by 118
Metformin versus insulin for gestational diabetes mellitus: a meta-analysis
Zhao, L., Sheng, X., Zhou, S., Yang, T., Ma, L., Zhou, Y., & Cui, Y. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12672 · Cited by 63
Metadata
- Authors
- Waugh, N., Royle, P., Clar, C., Henderson, R., Cummins, E., Hadden, D., Lindsay, R., & Pearson, D.
- Venue
- Health Technology Assessment
- Published
- 2010-09
- Volume
- 14
- Issue
- 45
- Pages
- 1-183
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W1994460353
- Cited by
- 60
- References
- 36
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.